세계의 혈소판풍부혈장(PRP) 시장 : 시장 규모, 점유율 및 동향, 업계 분석(유형별, 용도별, 최종 용도별, 지역별), 예측(2025-2034년)

The global platelet rich plasma (PRP) market size is expected to reach USD 2,857.98 million by 2034, according to a new study by Polaris Market Research. The report "Platelet Rich Plasma (PRP) Market Size, Share, Trends, & Industry Analysis Report By Type (Pure, Leukocyte, Pure Platelet-Rich Fibrin), By Application, By End Use, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Platelet rich plasma (PRP) is a key component in the field of regenerative medicine and therapeutic treatments, significantly transforming approaches in tissue repair and healing. Derived from a patient's own blood, PRP offers several advantages over conventional treatment methods, such as reduced risk of allergic reactions and faster recovery times. The growing demand for PRP is fueled by its safety, effectiveness, and natural healing properties, making it an increasingly preferred option across orthopedics, dermatology, sports medicine, and medical aesthetic procedures.

The PRP market is expanding rapidly due to ongoing scientific advancements and increasing demand in real world clinical settings. Government worldwide is supporting regenerative medicine through funding, research grants, and favorable regulations which is encouraging the development and adoption of PRP based treatments. Therefore, these factors have accelerated the usage of PRP therapies in areas such as tissue repair and musculoskeletal healing. Additionally, the growing prevalence of chronic conditions such as osteoarthritis, tendon injuries, and hair loss, which are often linked to aging populations and lifestyle changes, is further fueling demand for PRP. PRP further promotes tissue regeneration and healing, making it a valuable tool in both clinical and cosmetic applications.

The growing adoption of PRP treatments by plastic surgeons and dermatologists to enhance skin volume, tone, and texture has contributed significantly to the growth of the market. As the top minimally invasive procedure of 2023, the American Society of Plastic Surgeons reported nearly 5.9 million reconstructive procedures in the US alone.

Platelet Rich Plasma Market Report Highlights

Based on type, the pure platelet-rich plasma (P-PRP) or leukocyte-poor platelet-rich plasma segment dominated the platelet rich plasma market share in 2024, due to its distinct advantage with minimal risk and adverse effects, reducing concerns related to allergies and immune responses during treatments.

By application, the dermatology segment accounted for the largest share in 2024. The rapid growth is attributed to the growing demand for nonsurgical cosmetic surgery, such as skin rejuvenation, acne scar treatment, and hair restoration. Increased awareness of aesthetic treatments and the rising popularity of PRP for improving skin texture and hair growth significantly contributed to this growth. Dermatologists are using PRP to address diverse skin conditions, expanding treatment options.

North America dominated the global platelet rich plasma market revenue share in 2024. This market is primarily driven by increasing demand for cosmetic surgeries, a high prevalence of orthopedic procedures, and a rising incidence of sports-related injuries. Furthermore, micro-needling is gaining popularity for various applications, including transcutaneous drug administration, in addition to its original intended use for skin rejuvenation.

The platelet rich plasma market in Europe is experiencing significant growth, owing to the widespread adoption of PRP therapy for the treatment of musculoskeletal injuries. Conditions such as Achilles tendinopathy, plantar fasciitis, and tennis elbow are particularly contributing to this upward trend.

A few global key market players are Vivostat; Arthrex Inc.; RegenOrthoSport; Dr. PRP USA LLC; Juventix Regenerative Medical, LLC; Terumo Cardiovascular Systems Corporation; Zimmer Biomet; Isto Biologics; Apex Biologix; and Regen Lab SA.

Polaris Market Research has segmented the platelet rich plasma market report on the basis of type, application, end use, and region:

By Type Outlook (Revenue, USD Million, 2020-2034)

Pure Platelet-Rich Plasma (P-PRP)

Leukocyte-and Platelet-Rich Plasma (L-PRP)

Pure Platelet-Rich Fibrin (P-PRF) - or Leukocyte-Poor Platelet-Rich Fibrin

Leukocyte- and Platelet-Rich Fibrin (L-PRF)

By Application Outlook (Revenue, USD Million, 2020-2034)

Orthopedics

Sports Medicine

General Surgery

Dermatology

Ophthalmology

Neurology

Cardiology

Others

By End Use Outlook (Revenue, USD Million, 2020-2034)

Hospitals

Clinics

Others

By Regional Outlook (Revenue, USD Million, 2020-2034)

North America

US

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

Malaysia

Australia

Indonesia

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

Rest of Middle East & Africa

Latin America

Brazil

Argentina

Rest of Latin America

Table of Contents

Chapter 1. Introduction

• 1.1 Report Description
  • 1.1.1 Objective of the Study
  • 1.1.2 Market Scope
  • 1.1.3 Assumptions
• 1.2 Stakeholders

Chapter 2. Research Methodology

• 2.1 Research Methodology
• 2.2 Research Scope and Assumptions
• 2.3 Information Procurement
  • 2.3.1 Purchased Database
  • 2.3.2 Internal Database
  • 2.3.3 Secondary Sources
  • 2.3.4 Third Party Perspective
  • 2.3.5 Primary Research
• 2.4 Information Analysis
  • 2.4.1 Data Analysis Models
• 2.5 Market Formulation and Data Visualization
• 2.6 Data Validation and Publishing (Secondary Sources)

Chapter 3. Executive Summary

Chapter 4. Market Insights

• 4.1 Platelet Rich Plasma (PRP) - Industry snapshot
• 4.2 Platelet Rich Plasma (PRP) Market - Value Chain Analysis
  • 4.2.1 Platelet Rich Plasma (PRP) Market Dynamics
  • 4.2.2 Drivers and Opportunities
    • 4.2.2.1 Rise in demand of PRP in cosmetic surgeries and dermatology
    • 4.2.2.2 Increasing geriatric population, and rise in the occurrence of orthopaedic and sports injuries accelerate the PRP demand over the forecast period
  • 4.2.3 Restraints and Challenges
    • 4.2.3.1 High cost of PRP therapy and lack of reimbursement policy may hamper the market growth
• 4.3 Platelet Rich Plasma (PRP) Market - Porter's Five Forces
  • 4.3.1 Threat of Substitutes: (Low to Moderate)
  • 4.3.2 Threat of New Entrants: (Moderate to high)
  • 4.3.3 Bargaining power of buyers: (Low to Moderate)
  • 4.3.4 Bargaining power of suppliers: (Moderate to High)
  • 4.3.5 Competitive Rivalry: (Moderate to High)
• 4.4 Platelet Rich Plasma (PRP) Market - PESTLE Analysis
• 4.5 Covid-19 Impact Analysis & Industry Trends

Chapter 5. Platelet Rich Plasma (PRP) Market Assessment by Type

• 5.1 Introduction
• 5.2 Pure Platelet-Rich Plasma (P-PRP)
• 5.3 Leukocyte-and Platelet-Rich Plasma (L-PRP)
• 5.4 Pure Platelet-Rich Fibrin (P-PRF)
• 5.5 Leukocyte- and Platelet-Rich Fibrin (L-PRF)

Chapter 6. Platelet Rich Plasma (PRP) Market Assessment by Application

• 6.1 Introduction
• 6.2 Orthopedics
• 6.3 Sports Medicine
• 6.4 General Surgery
• 6.5 Dermatology
• 6.6 Ophthalmology
• 6.7 Neurology
• 6.8 Cardiology
• 6.9 Others

Chapter 7. Platelet Rich Plasma (PRP) Market Assessment by End-Use

• 7.1 Introduction
• 7.2 Hospitals
• 7.3 Clinics
• 7.4 Others

Chapter 8. Platelet Rich Plasma (PRP) Market Assessment by Region

• 8.1 Introduction
• 8.2 Platelet Rich Plasma (PRP) Market - North America
  • 8.2.1 North America Platelet Rich Plasma (PRP), By Type
  • 8.2.2 North America Platelet Rich Plasma (PRP), By Application
  • 8.2.3 North America Platelet Rich Plasma (PRP) Market, By End-Use
  • 8.2.4 Platelet Rich Plasma (PRP) Market - U.S.
    • 8.2.4.1 U.S. Platelet Rich Plasma (PRP), By Type
    • 8.2.4.2 U.S. Platelet Rich Plasma (PRP), By Application
    • 8.2.4.3 U.S. Platelet Rich Plasma (PRP), By End-Use
  • 8.2.5 Platelet Rich Plasma (PRP) Market - Canada
    • 8.2.5.1 Canada Platelet Rich Plasma (PRP), By Type
    • 8.2.5.2 Canada Platelet Rich Plasma (PRP), By Application
    • 8.2.5.3 Canada Platelet Rich Plasma (PRP), By End-Use
• 8.3 Platelet Rich Plasma (PRP) Market - Europe
  • 8.3.1 Europe Platelet Rich Plasma (PRP), By Type
  • 8.3.2 Europe Platelet Rich Plasma (PRP), By Application
  • 8.3.3 Europe Platelet Rich Plasma (PRP) Market, By End-Use
  • 8.3.4 Platelet Rich Plasma (PRP) Market - France
    • 8.3.4.1 France Platelet Rich Plasma (PRP), By Type
    • 8.3.4.2 France Platelet Rich Plasma (PRP), By Application
    • 8.3.4.3 France Platelet Rich Plasma (PRP), By End-Use
  • 8.3.5 Platelet Rich Plasma (PRP) Market - Germany
    • 8.3.5.1 Germany Platelet Rich Plasma (PRP), By Type
    • 8.3.5.2 Germany Platelet Rich Plasma (PRP), By Application
    • 8.3.5.3 Germany Platelet Rich Plasma (PRP), By End-Use
  • 8.3.6 Platelet Rich Plasma (PRP) Market - UK
    • 8.3.6.1 UK Platelet Rich Plasma (PRP), By Type
    • 8.3.6.2 UK Platelet Rich Plasma (PRP), By Application
    • 8.3.6.3 UK Platelet Rich Plasma (PRP), By End-Use
  • 8.3.7 Platelet Rich Plasma (PRP) Market - Italy
    • 8.3.7.1 Italy Platelet Rich Plasma (PRP), By Type
    • 8.3.7.2 Italy Platelet Rich Plasma (PRP), By Application
    • 8.3.7.3 Italy Platelet Rich Plasma (PRP), By End-Use
  • 8.3.8 Platelet Rich Plasma (PRP) Market - Netherlands
    • 8.3.8.1 Netherlands Platelet Rich Plasma (PRP), By Type
    • 8.3.8.2 Netherlands Platelet Rich Plasma (PRP), By Application
    • 8.3.8.3 Netherlands Platelet Rich Plasma (PRP), By End-Use
  • 8.3.9 Platelet Rich Plasma (PRP) Market - Spain
    • 8.3.9.1 Spain Platelet Rich Plasma (PRP), By Type
    • 8.3.9.2 Spain Platelet Rich Plasma (PRP), By Application
    • 8.3.9.3 Spain Platelet Rich Plasma (PRP), By End-Use
  • 8.3.10 Platelet Rich Plasma (PRP) Market - Russia
    • 8.3.10.1 Russia Platelet Rich Plasma (PRP), By Type
    • 8.3.10.2 Russia Platelet Rich Plasma (PRP), By Application
    • 8.3.10.3 Russia Platelet Rich Plasma (PRP), By End-Use
  • 8.3.11 Platelet Rich Plasma (PRP) Market - Rest of Europe
    • 8.3.11.1 Rest of Europe Platelet Rich Plasma (PRP), By Type
    • 8.3.11.2 Rest of Europe Platelet Rich Plasma (PRP), By Application
    • 8.3.11.3 Rest of Europe Platelet Rich Plasma (PRP), By End-Use
• 8.4 Platelet Rich Plasma (PRP) Market - Asia Pacific
  • 8.4.1 Asia Pacific Platelet Rich Plasma (PRP), By Type
  • 8.4.2 Asia Pacific Platelet Rich Plasma (PRP), By Application
  • 8.4.3 Asia Pacific Platelet Rich Plasma (PRP) Market, By End-Use
  • 8.4.4 Platelet Rich Plasma (PRP) Market - Japan
    • 8.4.4.1 Japan Platelet Rich Plasma (PRP), By Type
    • 8.4.4.2 Japan Platelet Rich Plasma (PRP), By Application
    • 8.4.4.3 Japan Platelet Rich Plasma (PRP), By End-Use
  • 8.4.5 Platelet Rich Plasma (PRP) Market - China
    • 8.4.5.1 China Platelet Rich Plasma (PRP), By Type
    • 8.4.5.2 China Platelet Rich Plasma (PRP), By Application
    • 8.4.5.3 China Platelet Rich Plasma (PRP), By End-Use
  • 8.4.6 Platelet Rich Plasma (PRP) Market - India
    • 8.4.6.1 India Platelet Rich Plasma (PRP), By Type
    • 8.4.6.2 India Platelet Rich Plasma (PRP), By Application
    • 8.4.6.3 India Platelet Rich Plasma (PRP), By End-Use
  • 8.4.7 Platelet Rich Plasma (PRP) Market - Malaysia
    • 8.4.7.1 Malaysia Platelet Rich Plasma (PRP), By Type
    • 8.4.7.2 Malaysia Platelet Rich Plasma (PRP), By Application
    • 8.4.7.3 Malaysia Platelet Rich Plasma (PRP), By End-Use
  • 8.4.8 Platelet Rich Plasma (PRP) Market - Indonesia
    • 8.4.8.1 Indonesia Platelet Rich Plasma (PRP), By Type
    • 8.4.8.2 Indonesia Platelet Rich Plasma (PRP), By Application
    • 8.4.8.3 Indonesia Platelet Rich Plasma (PRP), By End-Use
  • 8.4.9 Platelet Rich Plasma (PRP) Market - South Korea
    • 8.4.9.1 South Korea Platelet Rich Plasma (PRP), By Type
    • 8.4.9.2 South Korea Platelet Rich Plasma (PRP), By Application
    • 8.4.9.3 South Korea Platelet Rich Plasma (PRP), By End-Use
  • 8.4.10 Platelet Rich Plasma (PRP) Market - Australia
    • 8.4.10.1 Australia Platelet Rich Plasma (PRP), By Type
    • 8.4.10.2 Australia Platelet Rich Plasma (PRP), By Application
    • 8.4.10.3 Australia Platelet Rich Plasma (PRP), By End-Use
  • 8.4.11 Platelet Rich Plasma (PRP) Market - Rest of APAC
    • 8.4.11.1 Rest of APAC Platelet Rich Plasma (PRP), By Type
    • 8.4.11.2 Rest of APAC Platelet Rich Plasma (PRP), By Application
    • 8.4.11.3 Rest of APAC Platelet Rich Plasma (PRP), By End-Use
• 8.5 Platelet Rich Plasma (PRP) Market - Latin America
  • 8.5.1 Latin America Platelet Rich Plasma (PRP), By Type
  • 8.5.2 Latin America Platelet Rich Plasma (PRP), By Application
  • 8.5.3 Latin America Platelet Rich Plasma (PRP) Market, By End-Use
  • 8.5.4 Platelet Rich Plasma (PRP) Market - Mexico
    • 8.5.4.1 Mexico Platelet Rich Plasma (PRP), By Type
    • 8.5.4.2 Mexico Platelet Rich Plasma (PRP), By Application
    • 8.5.4.3 Mexico Platelet Rich Plasma (PRP), By End-Use
  • 8.5.5 Platelet Rich Plasma (PRP) Market - Brazil
    • 8.5.5.1 Brazil Platelet Rich Plasma (PRP), By Type
    • 8.5.5.2 Brazil Platelet Rich Plasma (PRP), By Application
    • 8.5.5.3 Brazil Platelet Rich Plasma (PRP), By End-Use
  • 8.5.6 Platelet Rich Plasma (PRP) Market - Argentina
    • 8.5.6.1 Argentina Platelet Rich Plasma (PRP), By Type
    • 8.5.6.2 Argentina Platelet Rich Plasma (PRP), By Application
    • 8.5.6.3 Argentina Platelet Rich Plasma (PRP), By End-Use
  • 8.5.7 Platelet Rich Plasma (PRP) Market - Rest of Latin America
    • 8.5.7.1 Rest of LATAM Platelet Rich Plasma (PRP), By Type
    • 8.5.7.2 Rest of LATAM Platelet Rich Plasma (PRP), By Application
    • 8.5.7.3 Rest of LATAM Platelet Rich Plasma (PRP), By End-Use
• 8.6 Platelet Rich Plasma (PRP) Market - Middle East Africa
  • 8.6.1 Middle East & Africa Platelet Rich Plasma (PRP), By Type
  • 8.6.2 Middle East & Africa Platelet Rich Plasma (PRP), By Application
  • 8.6.3 Middle East & Africa Platelet Rich Plasma (PRP) Market, By End-Use
  • 8.6.4 Platelet Rich Plasma (PRP) Market - Saudi Arabia
    • 8.6.4.1 Saudi Arabia Platelet Rich Plasma (PRP), By Type
    • 8.6.4.2 Saudi Arabia Platelet Rich Plasma (PRP), By Application
    • 8.6.4.3 Saudi Arabia Platelet Rich Plasma (PRP), By End-Use
  • 8.6.5 Platelet Rich Plasma (PRP) Market - South Africa
    • 8.6.5.1 South Africa Platelet Rich Plasma (PRP), By Type
    • 8.6.5.2 South Africa Platelet Rich Plasma (PRP), By Application
    • 8.6.5.3 South Africa Platelet Rich Plasma (PRP), By End-Use
  • 8.6.6 Platelet Rich Plasma (PRP) Market - Rest of MEA
    • 8.6.6.1 Rest of MEA Platelet Rich Plasma (PRP), By Type
    • 8.6.6.2 Rest of MEA Platelet Rich Plasma (PRP), By Application
    • 8.6.6.3 Rest of MEA Platelet Rich Plasma (PRP), By End-Use

Chapter 9. Competitive Landscape

• 9.1 Key Market Players: Categorization
• 9.2 Strategy Framework
• 9.3 Vendor Landscape
• 9.4 Strategies Categorization
  • 9.4.1 Launch/Approval/Development

Chapter 10. Company Profiles

• 10.1 Vivostat
  • 10.1.1 Business Overview
  • 10.1.2 Products and Services
• 10.2 Arthrex, Inc.
  • 10.2.1 Business Overview
  • 10.2.2 Products and Services
  • 10.2.3 Recent Developments
• 10.3 RegenOrthoSport
  • 10.3.1 Business Overview
  • 10.3.2 Products and Services
• 10.4 Dr PRP USA LLC
  • 10.4.1 Business Overview
  • 10.4.2 Products and Services
• 10.5 Juventix Regenerative Medical, LLC.
  • 10.5.1 Business Overview
  • 10.5.2 Products and Services
• 10.6 Terumo Cardiovascular Systems Corporation
  • 10.6.1 Business Overview
  • 10.6.2 Financial Snapshot
    • 10.6.2.1 Revenue by Geographic Region
  • 10.6.3 Products and Services
• 10.7 Zimmer Biomet
  • 10.7.1 Business Overview
  • 10.7.2 Financial Snapshot
    • 10.7.2.1 Net Sales by Geographic
    • 10.7.2.2 Net Sales by Product Category
  • 10.7.3 Products and Services
  • 10.7.4 Recent Developments
• 10.8 Isto Biologics
  • 10.8.1 Business Overview
  • 10.8.2 Products and Services
  • 10.8.3 Recent Developments
• 10.9 APEX Biologix
  • 10.9.1 Business Overview
  • 10.9.2 Products and Services
  • 10.9.3 Recent Developments
• 10.10 Regen Lab SA
  • 10.10.1 Business Overview
  • 10.10.2 Products and Services